Truist raised the firm’s price target on Biogen (BIIB) to $190 from $189 and keeps a Hold rating on the shares. The firm has updated its model after the company’s Q1 results, also maintaining its concerns regarding Biogen’s forward revenue growth trajectory, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $200 from $190 at Citi
- Biogen price target raised to $206 from $200 at Morgan Stanley
- Biogen Kept at Hold as Near-Term Growth Remains Constrained; Market Perform with Unchanged $196 Price Target
- Biogen price target raised to $222 from $213 at RBC Capital
- Andrew Fein Reiterates Buy on Biogen, Lifts Price Target to $237 on De‑Risked BIIB080 Alzheimer’s Opportunity